PMID- 38270296
OWN - NLM
STAT- MEDLINE
DCOM- 20240126
LR  - 20240206
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 12
IP  - 1
DP  - 2024 Jan
TI  - Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.
PG  - e1128
LID - 10.1002/iid3.1128 [doi]
LID - e1128
AB  - INTRODUCTION: To evaluate whether treated with immunosuppressants in 
      neuromyelitis optica spectrum disorder (NMOSD) shows an effect on the severity 
      and outcomes of COVID-19 Omicron variant. METHODS: This is a substudy of a 
      single-center clinical trial involving human umbilical cord mesenchymal stem 
      cells (hUC-MSCs) in NMOSD patients. NMOSD patients with hUC-MSCs treatment, NMOSD 
      patients without hUC-MSCs treatment, and matched healthy controls (HC) were 
      included. Demographic information, NMOSD-related clinical features, 
      comorbidities, use of disease-modifying therapy, COVID-19 vaccination status, 
      COVID-19 clinical features, COVID-19 clinical outcomes, and NMOSD-related disease 
      activity were obtained through online questionnaires or phone calls. RESULTS: The 
      majority of NMOSD patients received long-term treatment with mycophenolate 
      mofetil (68.8%) or azathioprine (22.9%), and 50% received oral glucocorticoid. 
      During the epidemic, 97.4% of NMOSD patients infected with COVID-19 had 
      asymptomatic or mild forms, with only two patients (2.6%) requiring 
      hospitalization. None of these patients required tracheal intubation or admission 
      to the intensive care unit. Clinical symptoms were found to be more prevalent in 
      HC groups. Additionally, the HC groups had higher fever-recorded temperatures. 
      NMOSD patients who received hUC-MSCs treatment had shorter disease duration than 
      patients who did not receive hUC-MSCs treatment. DISCUSSION: 
      Immunosuppressant-treated patients with NMOSD have a similar risk of COVID-19 
      infection as the general population, but the disease duration is shorter and the 
      clinical symptoms are less severe. Among our NMOSD patients who received hUC-MSCs 
      treatment, COVID-19 outcomes were favorable, with no increased risk of severe 
      COVID-19. Prospective studies on immunotherapies are needed to help determine 
      best treatment practices.
CI  - (c) 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Choi, Un Wai
AU  - Choi UW
AUID- ORCID: 0000-0002-5949-9526
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Ai, Xiwen
AU  - Ai X
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Li, Hongyan
AU  - Li H
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Hao, Yong
AU  - Hao Y
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Yao, Xiaoying
AU  - Yao X
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Guan, Yangtai
AU  - Guan Y
AD  - Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
LA  - eng
GR  - DLY201605/School of Medicine, Shanghai Jiao Tong University/
GR  - 81771295/National Natural Science Foundation of China/
GR  - 2020YFA0113100/Ministry of Science and Technology of the People's Republic of 
      China/
PT  - Journal Article
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (COVID-19 Vaccines)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Humans
MH  - COVID-19 Vaccines
MH  - *Neuromyelitis Optica/therapy
MH  - Prospective Studies
MH  - *COVID-19/therapy
MH  - SARS-CoV-2
MH  - Immunosuppression Therapy
PMC - PMC10790678
OTO - NOTNLM
OT  - COVID-19
OT  - human umbilical cord mesenchymal stem cell (hUC-MSC)
OT  - immunosuppressant
OT  - neuromyelitis optica spectrum disorder (NMOSD)
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/25 12:42
MHDA- 2024/01/26 06:43
PMCR- 2024/01/16
CRDT- 2024/01/25 08:19
PHST- 2023/11/20 00:00 [revised]
PHST- 2023/08/18 00:00 [received]
PHST- 2023/11/24 00:00 [accepted]
PHST- 2024/01/26 06:43 [medline]
PHST- 2024/01/25 12:42 [pubmed]
PHST- 2024/01/25 08:19 [entrez]
PHST- 2024/01/16 00:00 [pmc-release]
AID - IID31128 [pii]
AID - 10.1002/iid3.1128 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2024 Jan;12(1):e1128. doi: 10.1002/iid3.1128.